Background: The effect of controlled-onset, extendedrelease (COER) verapamil on haemodynamic parameters in obese and non-obese patients is evaluated in this analysis. Methods: Data were pooled from three clinical trials evaluating efficacy and tolerability of COER-verapamil. Hypertensive men and women (stage I to III) were randomised to COER-verapamil (180-540 mg at bedtime) or placebo for 4 -8 weeks and stratified according to body mass index (BMI-obese Ͼ28 kg/m 2 ). Efficacy was assessed as change from baseline in blood pressure (BP), heart rate, and rate-pressure product during four time periods throughout the dosing interval. Safety and tolerability were assessed by monitoring all adverse
Introduction
Obesity and essential hypertension are two common, coexisting risk factors for cardiovascular disease. The Framingham study showed that obesity is related to hypertension in as many as 70% of men and 61% of women. 1 Mechanisms that relate hypertension to obesity include increased insulin secretion, which leads to sodium retention, increased sympathetic nervous activity, and vascular hypertrophy; and peripheral insulin resistance, which may result in attenuated vasodilation. 2 The coexistence of hypertension and obesity is associated with serious end-organ damage, such as volume and pressure-induced left ventricular hypertrophy, renal dysfunction, peripheral vascular disease, and coronary artery disease. 3 Therefore, it is of particular importance to assure adequate blood pressure control in obese patients.
Weight loss and dietary sodium restriction help to lower blood pressure (BP) and are useful nonpharmacologic treatments for obese patients with hypertension. However, the beneficial effect of these measures on BP typically is limited due to poor longterm compliance by patients. 4, 5 Antihypertensive drug therapy, in addition to diet control, has been shown to be more effective than diet alone in controlling BP and decreasing cardiovascular risk. 6, 7 Because obesity is commonly associated with metabolic abnormalities such as insulin resistance and hyperlipidaemia, [8] [9] [10] diuretics and ␤-adrenergic blocking agents may not always be optimal therapy, especially at higher doses, due to their tendency to exacerbate these comorbidities. Angiotensinconverting enzyme (ACE) inhibitors, and calcium antagonists lack these adverse metabolic effects. Calcium antagonists are a good choice for BP reduction in obese patients for a number of reasons, including enhancement of sodium excretion, left ventricular mass regression, and neutral or potentially beneficial effects on glucose and insulin metabolism.
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Chronotherapy is a relatively new concept in the development of antihypertensive agents. The goal of chronotherapy is to coordinate the timing of drug release, and thus therapeutic effect, with human biological rhythms and physiologic requirements. Controlled-onset extended-release verapamil (COERverapamil) is a novel antihypertensive therapy developed to control the release of the calcium antagonist, verapamil, in synchrony with the circadian rhythm of BP and heart rate (HR). Because these haemodynamic parameters (and risk of adverse cardiovascular events: myocardial infarction, sudden cardiac death, and stroke [20] [21] ) peak in the earlymorning hours and gradually taper to lowest levels at night, COER-verapamil is formulated to reach its peak effect in the early-morning hours, with tapering, but still therapeutic, levels throughout the 24-h period. Although studies have demonstrated the safety and efficacy of COER-verapamil in the general population of patients with hypertension, [22] [23] [24] studies have not been performed in specific populations known to be at higher risk for cardiovascular disease, such as obese patients. The present analysis was undertaken to compare the efficacy and tolerability of the first chronotherapeutic formulation of a calcium antagonist, COER-verapamil, in obese vs non-obese patients with hypertension.
Methods
Study design
Data were pooled from three North American, multicentre, double-blind, randomised, prospective, placebo-controlled, and parallel-group clinical trials of COER-verapamil in patients with stage I to III hypertension. All trials included a 1-to 2-week washout period followed by a 2-to 4-week, single-blind, placebo phase to establish baseline haemodynamic values. Patients then were randomised to 4 to 8 weeks of double-blind treatment with either COERverapamil (180 to 540 mg) or placebo. Treatment doses were administered once daily at 10 pm. Ambulatory BP monitoring was used in all trials to assess the change from baseline in BP, HR, and heart rate-systolic pressure product (RPP).
Patient population
At the end of the single-blind placebo phase, men and women with an average seated diastolic BP of 95 to 115 mm Hg on 2 consecutive weeks measured by mercury sphygmomanometry (both readings within 8 mm Hg of each other) and a mean daytime ambulatory diastolic BP Ͼ90 mm Hg entered the double-blind treatment phase. Patients were classified as obese if their body mass index (BMI) was greater than or equal to 28 kg/m 2 . Studies were approved by each investigator's institutional review board and informed consent was obtained from patients prior to any study procedure.
Patients were excluded from the trials if they had known secondary hypertension, coronary artery disease, congestive heart failure, high-grade cardiac conduction abnormalities, alcoholism, psychosis, serious chronic medical diseases (eg, hepatic or renal insufficiency), or malabsorption syndromes. Patients who worked at night or worked various shifts also were excluded.
Study measurements
The primary efficacy variables were defined as the change from baseline in mean BP and HR values measured during four time intervals: early morning (6 am to 10 am), daytime (8 am to 8 pm), night-time (8 pm to 8 am), and 24-h mean. Ambulatory BP monitoring (Spacelabs model 90202, Redmond, WA, USA) was used to assess the change from baseline in these BP and heart rate parameters. Patients underwent monitoring for 36 h at the end of the washout period and at completion of double-blind treatment. Blood pressure and HR were measured every 15 min for the entire study period. In order for BP recordings to be included in the analysis, at least 80% of the readings in the 24-h post-dose period must have been valid, with a minimum of two valid readings per hour during the first 20 h and a minimum of three valid readings per hour during at least 3 of the last 4 h. If measurements failed to meet these criteria, patients were asked to repeat the study within 2 days. Patients whose ambulatory BP monitoring studies failed to meet the above criteria were considered non-evaluable. Patients included in the final efficacy analysis were those who had evaluable ambulatory BP readings at the end of the placebo baseline phase and at the end of double-blind treatment. All statistical comparisons of efficacy measurements were performed using two-tailed ttests. The a priori level of significance for all efficacy measurements was P Ͻ 0.05.
Tolerability and safety of COER-verapamil were assessed by monitoring the incidence of new clinical abnormalities appearing in treated patients compared with placebo. These new clinical abnormalities were defined as adverse events reported after treatment with the study drug that was either not reported during the placebo baseline or was reported during baseline but worsened in severity during double-blind treatment. The analysis of tolerability and safety included all patients who received at least one dose of the study drug. Incidence rates of adverse events were compared using two-tailed Fisher exact tests. Any adverse event that was statistically different than placebo was considered to be of potential clinical significance.
To assess metabolic effects of COER-verapamil, laboratory parameters, including blood urea nitrogen (BUN), total cholesterol, serum creatinine, serum glucose, serum potassium, serum triglycerides, serum uric acid, and urine protein were measured at baseline and at the end of double-blind treat- 
ment. Significant differences in laboratory parameters were detected using an analysis of variance (ANOVA).
Results
For the efficacy analyses, 394 patients (229 obese vs 165 non-obese) were evaluable based on the completion of both baseline and double-blind treatment ambulatory BP monitoring studies. There were 437 patients (249 obese vs 188 non-obese) included in the safety and tolerability analyses. The baseline characteristics of the various subgroups according to BMI and drug treatment groups are shown in Tables  1 and 2 . With the exception of the BMI, there were 
Efficacy of COER-verapamil in obese vs non-obese patients
The changes from baseline in ambulatory BP for the four different time periods are shown in Figure 1 and Table 3 for the obese vs non-obese subgroups. With the exception of a slightly greater placebo-subtracted reduction in the early morning systolic pressure in the non-obese group (−16.0 vs −14.8 mm Hg, P = 0.040 in non-obese vs obese, respectively), all changes in BP were similar for the two patient subgroups. Similarly, the mean changes from baseline in ambulatory heart rates ( Figure 2 ) and the heart rate-systolic BP products ( Figure 3 ) were statistically and clinically similar for the obese and non-obese patient populations.
Efficacy of COER-verapamil vs placebo
The mean changes from baseline in the haemodynamic parameters for COER-verapamil vs placebo in both the obese and non-obese patients are shown in Table 3 . At all time periods in both groups, COERverapamil reduced BP, heart rate, and the rate-pressure product to a greater extent than placebo. In the obese patient group, the largest reductions in BP were observed during the early morning period (−14.5/−11.5 mm Hg vs 0.3/0.7 mm Hg for placebo, P Ͻ 0.001 vs placebo for both systolic and diastolic pressure). Lesser but significant reductions in BP occurred during the night-time period (−9.1/−6.8 mm Hg, P Ͻ 0.001 vs placebo). Similar findings were demonstrated for the non-obese patients with a reduction in early morning BP of −17.8/−13.5 mm Hg.
The effects of COER-verapamil on heart rate and the rate-pressure product vs placebo are also shown in Table 3 . COER-verapamil induced statistically significant reductions in heart rate for all time periods in both patient subgroups compared with placebo. The average reductions in heart rate were approximately 7 beats/min during the daytime and 3 beats/min during the night-time. Similarly, the drug significantly lowered the rate-pressure product by approximately 2000 mm Hg-beats/min in the early morning period and during the daytime, and by 1000-1200 mm Hg-beats/min during the night-time period. The daytime reductions in the rate-pressure product were about 15% lower than baseline (Table  2) , while the night-time reductions were approximately 10% lower than baseline values.
Safety and tolerability of COER-verapamil in obese vs non-obese patients
New clinical abnormalities reported with an incidence of у5% for placebo or COER-verapamil in either subgroup are shown in Table 4 . For the obese patient group, there were no significant differences in these adverse event rates in COER-verapamiltreated patients vs placebo-treated patients. In the non-obese patient group, fatigue and constipation occurred more commonly with COER-verapamil than with placebo. Comparisons between the subgroups also showed that the rates of constipation (5.7% vs 18.3%) and fatigue (1.7% vs 10.8%) were significantly less (P Ͻ 0.001) in the obese patients compared to the non-obese patients.
There were no statistically nor clinically significant differences in the changes from baseline of the metabolic laboratory parameters between the obese and non-obese subgroups following COER-verapamil treatment. In the obese patient population, there was a small, statistically significant, increase in serum glucose of 3 mg/dL for COER-verapamil vs −3 mg/dL for placebo (P = 0.043). In the non-obese patient group, there was a small, statistically significant, decrease in serum uric acid on COER-verapamil (−0.3 mg/dL with COER-verapamil vs 0.0 mg/dL with placebo, P = 0.045). These two metabolic changes observed on COER-verapamil were not considered to be clinically relevant.
Discussion
The principal findings of our study demonstrate that obese patients with hypertension achieved signifi- 0.7 ± 7.7 −11.5 ± 9.2* −1.4 ± 6.4 −13.5 ± 9.9* 0.083 cant reductions in BP, heart rate, and the rate-pressure product at all time intervals during the dosing period with controlled-onset extended release (COER-24) verapamil. As shown in Figures 1, 2 and 3, these changes from baseline in the obese group generally were comparable to those obtained in the non-obese patients. Due to the chronotherapeutic delivery system of COER-verapamil, 22, 23 BP was reduced to the greatest extent during the early-morning hours for both populations. Lesser but statistically significant reductions in BP, heart rate, and the rate-pressure product were observed at night-time, the time period when the BP and rate-pressure product are typically at their lowest. 24 Prior to the present study, the concept of matching drug delivery to circadian BP, heart rate, and myocardial ischaemia rhythms was tested pharmacodynamically and clinically with this novel delivery system for verapamil (COER-verapamil). [22] [23] [24] [25] This system has a delay in release of verapamil for approximately 4 to 5 h after administration and then an extended release of drug for approximately 18 h. 22 When taken at bedtime, the COER-24 system provides optimal concentrations from 8 to 12 h post- dosing, a time period that typically coincides with the early-morning surge in BP and heart rate. 20, 26 This delivery system yields haemodynamic effects that are greatest during the early-morning periodwhen cardiovascular risk is greatest -remain clinically effective during the daytime, and are smaller during sleep, when cardiovascular demands are less. Our data (Table 3 and Figures 1-3 ) demonstrate that COER-verapamil induces these chronotherapeutic effects in obese patients similarly compared with non-obese patients. The chronotherapeutic effects of COER-verapamil have been demonstrated in the hypertensive patient population in general. 22, 23 Additionally, a study in African-American patients treated with COER-verapamil showed significant reductions in BP and the rate-pressure product during the 24-h treatment period with the greatest reductions in haemodynamic parameters occurring in the early morning period. 27 These findings in African-American patients with hypertension were similar to the results of a study that evaluated the effects of COER-verapamil according to the circadian BP profile in a predominantly Caucasian hypertensive population. 26, 28 Evaluation of the safety and tolerability of COERverapamil in the subgroup analyses demonstrated that most adverse event rates were similar for hypertensive patients with obesity compared with the non-obese patients (Table 4) . Two notable exceptions were that obese patients had significantly lower rates of constipation and fatigue compared to the non-obese group. In fact, for the obese patient subgroup, there were no significant differences in the incidence rates of new clinical abnormalities for COER-verapamil vs placebo (Table 4) . Thus, COERverapamil may be particularly well tolerated in hypertensive patients with increased body mass indexes. A recent study by Anderson et al 29 demonstrated that when using a symptom-related distress score obtained by patients and their spouses as an index of quality of life, COER-verapamil showed similar rates of constipation to nifedipine GITS. These data suggested, along with the primary trial results from that same study, 24 that gastrointestinal side effects with this drug are modest and often self-limiting.
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Common metabolic parameters such as renal function, serum glucose, and lipids were clinically unaffected by COER-verapamil in both obese and nonobese patients with hypertension. This finding is of particular importance in the obese patient with hypertension, since both obesity and hypertension are typically associated with insulin resistance, hyperinsulinaemia, glucose intolerance, and dyslipidaemia. 2 Our study shows that the ability of COER-verapamil to lower the ambulatory BP, heart rate, and the rate-pressure product was not affected by BMI. The chronotherapeutic delivery system of this agent makes it a valuable therapeutic alternative for obesity-related hypertension by combining the advantages of a heart rate-lowering calcium antagonist with drug delivery at the times of greatest need from the perspective of circadian physiology. 21 Furthermore, COER-verapamil is an ideal agent for reduction in the rate-pressure product at peak times for myocardial ischaemia and events. 24 The data from the ongoing 16 605-patient international clinical trial known as Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE), 30 will be of great relevance in demonstrating whether this chronobiologic agent will yield reductions in fatal and nonfatal myocardial infarction and stroke compared with a standard therapeutic regimen dosed in the morning upon arising. CONVINCE is unique in that one of the cardiovascular risk factors which leads to eligibility in the trial is obesity; nearly half of the enrolled patients have BMI Ͼ28.5 kg/m 2 . Furthermore, the CONVINCE trial differs from other large-scale outcome studies in that it will provide an estimate of the effectiveness of a chronotherapeutic antihypertensive agent in preventing cardiovascular endpoints. 
